Core Viewpoint - Despite recent declines, certain growth stocks are still considered strong long-term investment opportunities due to their potential for recovery and growth [1]. Group 1: Viking Therapeutics (VKTX) - Viking Therapeutics' stock is down nearly 57% from its 52-week high of $81.73, primarily due to concerns over the high discontinuation rate of its leading drug VK2735 in clinical trials [4][5]. - The company is still developing VK2735, with an injectable version in late-stage trials, which could serve as a significant growth catalyst if approved [5][7]. - Currently, Viking Therapeutics has a market cap of $4 billion, with a current stock price of $38.17, and it has shown potential for weight loss of up to 14.7% after 13 weeks of treatment [6][7]. Group 2: Cava Group (CAVA) - Cava Group's share prices have decreased over 46% this year and are down nearly 65% from their 52-week high of $172.43, attributed to a slowdown in growth [8][9]. - The company's same-store sales growth was only 2.1% in the most recent quarter, a significant drop from 14.4% a year ago, yet it remains positive amid challenging economic conditions [9]. - Cava Group has plans to expand from 400 to 1,000 locations by 2032, indicating potential for future growth despite current challenges [9][11]. Group 3: Figma (FIG) - Figma's stock has fallen from a high of $142.92 to around $53, reflecting a significant decline since its public debut [12][15]. - The company has a market cap of $24 billion and reported $249.6 million in revenue for the period ending June 30, representing a 41% increase year-over-year [13][15]. - Figma's valuation is comparable to Adobe's previous bid of $20 billion for the company, suggesting it may be undervalued at its current price [13][15].